A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

NCT02368665 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: Amlodipine 5mg
DRUG: Amlodipine 5mg, Candesartan cilexetil 16mg
DRUG: Amlodipine 10mg, Candesartan cilexetil 16mg

Sponsor

HK inno.N Corporation